Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis?

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 5, 1998, Pages 271-276

  Rodriguez, Gustavo C ^a   Walmer, David K ^a,b   Cline, Mark ^c   Krigman, Hannah ^d   Lessey, Bruce A ^e   Whitaker, Regina S ^a   Dodge, Richard ^f   Hughes, Claude L ^a  

^a DUKE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f DUKE CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Oral contraceptives; Ovarian cancer; Progestins

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; MACACA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; EPITHELIAL CELLS; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; LEVONORGESTREL; MACACA FASCICULARIS; OVARIAN NEOPLASMS; OVARY;

EID: 0031783028     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(98)00017-3     Document Type: Article

References (43)

1. Cancer Facts and Figures. 1996. American Cancer Society, Yearly Publication. Atlanta, Georgia: American Cancer Society.
2. Rosenberg L., Palmer J.R., Zauber A.G., et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 139:1994;654-661.
3. Stanford J.L., Thomas D.B., Ray R.M., Noonan E.A. Epithelial ovarian cancer and combined oral contraceptives The WHO collaborative study of neoplasia and steroid contraceptives . Int J Epidemiol. 18:1989;538-545.
4. Lee N.C., Wingo P.A., Gwynn M.L., et al. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med. 316:1987;650-655.
5. Gross T.P., Schlesselman J.J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 83:1994;419-424.
6. Franceschi S., Parazzini F., Negri E., et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer III. Oral contraceptive use . Int J Cancer. 49:1991;61-65.
7. Wu M.L., Whittemore A.S., Paffenbarger R.S. Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidem. 28:1987;1216-1227.
8. Greene M.H., Clark J.W., Blayney D.W. The epidemiology of ovarian cancer. Semin Oncol. 2:1984;209-225.
9. Brenner R.M., Slayden O.D. Cyclic changes in the primate oviduct and endometrium. Knobil E., Neill J.D. The physiology of reproduction. 1994;541-569 Lippincott-Raven, Philadelphia.
10. Hotchkiss J., Knobil E. The menstrual cycle and its neuroendocrine control. Knobil E., Neill J.D. The physiology of reproduction. 1994;711-736 Lippincott-Raven, Philadelphia.
11. Kaiserman-Abramof I., Padykula H. Ultrastructural epithelial zonation of the primate endometrium (rhesus monkey). Am J Anat. 184:1989;13-30.
12. Wijsman J.H., Jonker R.R., Keijzer R., van de Velde C.J.H., Cornelisse C.J., van Dieriendonck J.H. A new method to detect apoptosis in paraffin sections In situ end-labeling of fragmented DNA . J Histochem Cytochem. 41:1993;7-12.
13. Hollander M., Wolfe D.A. Nonparametric statistical methods. 1973;Wiley, New York.
14. BMDP statistical software manual. Los Angeles: University of California Press, 1992:459-61.
15. Ferenczy A. Anatomy and histology of the uterine corpus. Korman J. Blaustein's pathology of the female genital tract. 3rd ed. 1987;257-291 Springer-Verlag, New York.
16. Lockshin R.A., Zakeri Z. The biology of cell death and its relationship to aging. Cellular aging and cell death. 1996;167-180 Wiley-Liss, New York.
17. Lowe S.W., Ruley H.E. p53-Dependent apoptosis in tumor progression and in cancer therapy. Cellular aging and cell death. 1996;209-234 Wiley-Liss, New York.
18. Canman C.E., Chen C.-Y., Lee M.-H., Kastian M.B. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symposia on Quantitative Biology. Vol. LIX:1994;277-286 Cold Spring Harbor Laboratory Press, Plainnow, NY.
19. Chan L.N., Zhang S., Cloyd M., et al. N-(4-hydroxyphenyl) retinamide prevents development of T-lymphomas in AKR/J mice. Anticancer Res. 17:1997;499-503.
20. Ponzoni M., Bocca P., Chiesa V., et al. Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells Apoptosis versus differentiation . Cancer Res. 55:1995;853-861.
21. Delia D., Aiello A., Lombardi L., et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 53:1993;6036-6041.
22. Seewaldt V.L., Kim J.H., Caldwell L.E., Johnson B.S., Swisshelm K., Collins S.J. All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ. 6:1995;863-869.
23. Lotan R. Retinoids in cancer chemoprevention. (review) FASEB J. 10:1996;1031-1039.
24. Sankaranarayanan R., Mathew B. Retinoids as cancer-preventive agents (review). IARC Sci. 139:1996;47-59.
25. Toma S., Isnardi L., Raffo P., et al. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines Growth inhibition and apoptosis induction . Int J Cancer. 70:1997;619-627.
26. Oridate N., Lotan D., Mitchell M.F., Hong W.K., Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids Implications for chemoprevention . J Cell Biochem Suppl. 23:1995;80-86.
27. Dolivet V., Ton Van J., Sarini J., et al. Current knowledge on the action of retinoids in carcinoma of the head and neck. [Review] Rev Laryngol Otol Rhinol (Bord). 117:1996;19-26.
28. Kuo S.M. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett. 110:1996;41-48.
29. Thompson H.J., Jiang C., Lu J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;267-271.
30. Reddy B.S., Wang C.X., Samaha H., et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res. 57:1997;420-425.
31. Gould M.N. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect. 105:(Suppl):1997;977-979.
32. Pascale R.M., Simile M.M., De Miglio M.R., et al. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis. 16:1995;427-430.
33. Thompson H.J., Wilson A., Lu J., et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis. 15:1994;183-186.
34. el-Bayoumy K., Upadhyaya P., Chae Y.H., et al. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl. 22:1995;92-100.
35. Casagrande J.T., Pike M.C., Ross R.K., Louie E.W., Roy S., Henderson B.E. "Incessant ovulation" and ovarian cancer. Lancet. 2:(8135):1979;170-173.
36. Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk Collaborative analysis of 12 US case-control studies . Am J Epidemiol. 136:1992;1212-1220.
37. Bast R.C. Jr, Berchuck A. Ovarian cancer. Isselbacher K.J., Braunwold E., Wilson J.D., Martin J.B., Fauci A.S., Kaspey D.L. Principles of internal medicine. 1994;1853-1858 McGraw-Hill, New York.
38. Rossing M.A., Daling J.R., Weiss N.S., Moore D.E., Self S.G. Ovarian tumors in a cohort of infertile women. N Engl J Med. 331:1994;771-776.
39. Hild-Petito S., Stouffer R.L., Brenner R.M. Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle. Endocrinology. 123:1988;2896-2905.
40. Press M.F., Greene G.L. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology. 122:1988;1165-1175.
41. Liang A.P., Levenson A.G., Layde P.M., et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA. 249:1983;2909-2912.
42. Stanford J.L., Thomas D.B. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer. 49:1991;191-195.
43. Rodriguez C., Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol. 141:1995;828-835.